A Study of Efavirenz in Combination With Stavudine and Didanosine
Phase 2
Completed
- Conditions
- HIV Infections
- Registration Number
- NCT00002225
- Lead Sponsor
- Dupont Merck
- Brief Summary
The purpose of this study is to see if it is safe and effective to give efavirenz plus stavudine plus didanosine to HIV-infected patients who have never received anti-HIV treatment.
- Detailed Description
Patients will be given combination treatment with efavirenz, stavudine, and didanosine.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (5)
Univ of Rochester Med Ctr
🇺🇸Rochester, New York, United States
AIDS Research Alliance - Chicago
🇺🇸Chicago, Illinois, United States
North Shore AIDS Hosp / Division of Infectious Disease
🇺🇸Manhassett, New York, United States
The Whitman Walker Clinic
🇺🇸Washington, District of Columbia, United States
Carolinas Research Associates
🇺🇸Charlotte, North Carolina, United States